24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk

被引：0
|
作者：
Toshitsugu Sugimoto
Masataka Shiraki
Masao Fukunaga
Hiroshi Hagino
Teruki Sone
Tetsuo Nakano
Hideaki Kishimoto
Masako Ito
Hideki Yoshikawa
Mitsukazu Kishida
Chika Irie
Toshitaka Nakamura
机构：
[1] Shimane University Faculty of Medicine,Internal Medicine 1
[2] Research Institute and Practice for Involutional Diseases,School of Health Science
[3] Kawasaki Medical School,Department of Nuclear Medicine
[4] Tottori University,Center for Diversity and Inclusion
[5] Kawasaki Medical School,Department of Orthopaedic Surgery, Graduated School of Medicine
[6] Tamana Central Hospital,undefined
[7] Nojima Hospital,undefined
[8] Nagasaki University,undefined
[9] Osaka University,undefined
[10] Asahi Kasei Pharma Corporation,undefined
[11] Touto Sangenjaya Rehabilitation Hospital,undefined
来源：
Advances in Therapy | 2017年 / 34卷
关键词：
Bone mineral density; Once-weekly injection; Osteoporosis; Radius; Teriparatide; Treatment response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1727 / 1740
页数：13
相关论文
共 21 条
  • [1] 24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
    Sugimoto, Toshitsugu
    Shiraki, Masataka
    Fukunaga, Masao
    Hagino, Hiroshi
    Sone, Teruki
    Nakano, Tetsuo
    Kishimoto, Hideaki
    Ito, Masako
    Yoshikawa, Hideki
    Kishida, Mitsukazu
    Irie, Chika
    Nakamura, Toshitaka
    [J]. ADVANCES IN THERAPY, 2017, 34 (07) : 1727 - 1740
  • [2] Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial
    Nakano, Tetsuo
    Shiraki, Masataka
    Sugimoto, Toshitsugu
    Kishimoto, Hideaki
    Ito, Masako
    Fukunaga, Masao
    Hagino, Hiroshi
    Sone, Teruki
    Kuroda, Tatsuhiko
    Nakamura, Toshitaka
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2014, 32 (04) : 441 - 446
  • [3] Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial
    Tetsuo Nakano
    Masataka Shiraki
    Toshitsugu Sugimoto
    Hideaki Kishimoto
    Masako Ito
    Masao Fukunaga
    Hiroshi Hagino
    Teruki Sone
    Tatsuhiko Kuroda
    Toshitaka Nakamura
    [J]. Journal of Bone and Mineral Metabolism, 2014, 32 : 441 - 446
  • [4] ONCE-WEEKLY TERIPARATIDE REDUCES VERTEBRAL FRACTURE RISK: SUBGROUP ANALYSIS FROM THE TERIPARATIDE ONCE WEEKLY EFFICACY RESEARCH (TOWER) TRIAL
    Nakamura, Y.
    Kuroda, T.
    Sugimoto, T.
    Shiraki, M.
    Nakano, T.
    Kishimoto, H.
    Ito, M.
    Fukunaga, M.
    Hagino, H.
    Sone, T.
    Nakamura, T.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S293 - S293
  • [5] Once-weekly Teriparatide Reduces Vertebral Fracture Risk - Subgroup Analysis from the Teriparatide Once Weekly Efficacy Research (TOWER) Trial
    Sugimoto, Toshitsugu
    Shiraki, Masataka
    Nakano, Tetsuo
    Kishimoto, Hideaki
    Ito, Masako
    Fukunaga, Masao
    Hagino, Hiroshi
    Sone, Teruki
    Nakamura, Toshitaka
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [6] Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial
    Sugimoto, Toshitsugu
    Shiraki, Masataka
    Nakano, Tetsuo
    Kishimoto, Hideaki
    Ito, Masako
    Fukunaga, Masao
    Hagino, Hiroshi
    Sone, Teruki
    Kuroda, Tatsuhiko
    Nakamura, Toshitaka
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (03) : 195 - 203
  • [7] Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
    Nakamura, Toshitaka
    Sugimoto, Toshitsugu
    Nakano, Tetsuo
    Kishimoto, Hideaki
    Ito, Masako
    Fukunaga, Masao
    Hagino, Hiroshi
    Sone, Teruki
    Yoshikawa, Hideki
    Nishizawa, Yoshiki
    Fujita, Takuo
    Shiraki, Masataka
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (09): : 3097 - 3106
  • [8] Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases
    Miyauchi, Akimitsu
    Matsumoto, Toshio
    Sugimoto, Toshitsugu
    Tsujimoto, Mika
    Warner, Margaret R.
    Nakamura, Toshitaka
    [J]. BONE, 2010, 47 (03) : 493 - 502
  • [9] Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
    Nanki, Toshihiro
    Kawazoe, Mai
    Uno, Kiyoko
    Hirose, Wataru
    Dobashi, Hiroaki
    Kataoka, Hiroshi
    Mimura, Toshihide
    Hagino, Hiroshi
    Kono, Hajime
    [J]. JOURNAL OF CLINICAL MEDICINE, 2023, 12 (01)
  • [10] FRACTURE RISK REDUCTION OF WEEKLY TERIPARATIDE FOR 72 WEEKS AND SUBSEQUENT 1 YEAR FOLLOW-UP IN TERIPARATIDE ONCE-WEEKLY EFFICACY RESEARCH (TOWER) TRIAL
    Kuroda, Tatsuhiko
    Sugimoto, Toshitsugu
    Shiraki, Masataka
    Nakano, Tetsuo
    Kishimoto, Hideaki
    Ito, Masako
    Fukunaga, Masao
    Hagino, Hiroshi
    Sone, Teruki
    Nakamura, Toshitaka
    [J]. OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S366 - S367
123